StockData
Johnson & Johnson logo

Johnson & Johnson

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$270.56−2.64 (-0.97%)

Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%

Johnson & Johnson Consumer Health Segment Total [spun off as Kenvue in by Quarter

Consumer Health Segment Total [spun off as Kenvue in FY2023Q3] — International operational growth YoY (%) (%)

QuarterlyAnnual

Johnson & Johnson Consumer Health Segment Total [spun off as Kenvue in: 9.0% in Q2 2023, up 1.7 pts from a year earlier. No newer figure appears in the documents we track.

Latest, Q2 2023
9.0%
Period ended Jul 2, 2023
Change on a year earlier
+1.7 pts
7.3% in Q2 2022
History
23 quarters
Since Q4 2017
Sources
23
Documents cited below

Where the Q2 2023 figure comes from

“|| Intl | 2,224 | 2,118 | 5.0 | 9.0 | (4.0)”

Source: Form 8-K (a2023q2exhibit991.htm, filed 2023-07-20) ↗

Reported in Form 8-K EX-99.2 Segment Sales Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedConsumer Health Segment Total [spun off as Kenvue in FY2023Q3] — International operational growth YoY (%) (%)Year on yearSource
Q2 2023Jul 2, 20239.0%+1.7 ptsForm 8-K (a2023q2exhibit991.htm, filed 2023-07-20) ↗
Q1 2023Apr 2, 202311.3%+7.2 ptsForm 8-K (a2023q1exhibit991.htm, filed 2023-04-18) ↗
Q4 2022Jan 1, 20233.2%+1.1 ptsForm 8-K (a2022q4exhibit991.htm, filed 2023-01-24) ↗
Q3 2022Oct 2, 20226.7%+3.0 ptsForm 8-K (a2022q3exhibit991.htm, filed 2022-10-18) ↗
Q2 2022Jul 3, 20227.3%+1.0 ptsForm 8-K (a2022q2exhibit991.htm, filed 2022-07-19) ↗
Q1 2022Apr 3, 20224.1%+3.6 ptsForm 8-K (a2022q1exhibit991.htm, filed 2022-04-19) ↗
Q4 2021Jan 2, 20222.1%+0.6 ptsForm 8-K (a2021q4exhibit991.htm, filed 2022-01-25) ↗
Q3 2021Oct 3, 20213.7%+6.4 ptsForm 8-K (a2021q3exhibit991.htm, filed 2021-10-19) ↗
Q2 2021Jul 4, 20216.3%+13.7 ptsForm 8-K (a2021q2exhibit991final.htm, filed 2021-07-21) ↗
Q1 2021Apr 4, 20210.5%-3.4 ptsForm 8-K (a2021q1exhibit991final.htm, filed 2021-04-20) ↗
Q4 2020Jan 3, 20211.5%-2.5 ptsForm 8-K (a2020q4exhibit991.htm, filed 2021-01-26) ↗
Q3 2020Sep 27, 2020-2.7%-7.0 ptsForm 8-K (a2020q3exhibit991.htm, filed 2020-10-13) ↗
Q2 2020Jun 28, 2020-7.4%-12.3 ptsForm 8-K (a2020q2exhibit991.htm, filed 2020-07-16) ↗
Q1 2020Mar 29, 20203.9%+0.2 ptsForm 8-K (a2020q1exhibit991.htm, filed 2020-04-14) ↗
Q4 2019Dec 29, 20194.0%+3.2 ptsForm 8-K (a2019q4exhibit991.htm, filed 2020-01-22) ↗
Q3 2019Sep 29, 20194.3%+0.6 ptsForm 8-K (a2019q3exhibit991.htm, filed 2019-10-15) ↗

Cite this data

StockData. (2026). Johnson & Johnson Consumer Health Segment Total [spun off as Kenvue in (%), quarterly Q4 2017–Q2 2023 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/seg-consumer-legacy-intl-ops-yoy

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.